D-Wave Quantum falls nearly 3% as earnings miss overshadows revenue beat
In a recent SEC filing, Fennec Pharmaceuticals Inc. (NASDAQ:FENC), a $181 million market cap pharmaceutical company with an impressive 93.5% gross profit margin and "GREAT" financial health score according to InvestingPro, disclosed that Director Rosty Raykov sold 10,000 common shares of the company on March 5, 2025. The shares were sold at a price of $6.79 each, amounting to a total transaction value of $67,900. Following this sale, Raykov retains 68,725 shares in the company. The transaction was conducted under a 10b5-1 trading plan, which was established on August 23, 2024. The stock has shown strong momentum with a 27.6% gain over the past six months, and currently trades near its InvestingPro Fair Value. Discover 8 more key insights about FENC and access the comprehensive Pro Research Report, available exclusively with an InvestingPro subscription.
In other recent news, Fennec Pharmaceuticals Inc. has announced significant developments regarding its product, PEDMARQSI, a sodium thiosulfate injection for preventing cisplatin-induced hearing loss in pediatric cancer patients. The company, in partnership with Norgine Pharmaceuticals Ltd., has launched PEDMARQSI in Germany, marking an important step in its European commercialization. This follows an exclusive licensing agreement that allows Norgine to market the drug in Europe, Australia, and New Zealand, with Fennec receiving an upfront payment of approximately $43 million and potential additional payments up to $230 million. The European Commission granted marketing authorization for PEDMARQSI in June 2023, providing data and market protection for ten years.
Furthermore, the National Institute for Health and Care Excellence (NICE) in England and Wales has issued final draft guidance endorsing PEDMARQSI for the same indication, reflecting the drug’s significance in addressing the unmet need for pharmacological prevention of ototoxicity. Clinical trials have shown that PEDMARQSI can reduce the risk of hearing loss by about 50% in children treated with cisplatin, a common chemotherapeutic agent. PEDMARQSI is also FDA approved in the U.S. under the name PEDMARK and is recommended by the National Comprehensive Cancer Network for pediatric patients with localized, non-metastatic solid tumors. Despite these advancements, the treatment requires careful monitoring due to potential risks such as hypersensitivity reactions and electrolyte imbalances. These developments underscore Fennec’s commitment to improving the standard of care for pediatric cancer patients globally.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.